The SELECT Trial and Differentiated Thyroid Cancer

Lori Wirth, MD provides an overview of differentiated thyroid cancer and reviews key data from the SELECT trial examining the use of lenvatinib.

EP. 1: Overview and Diagnosis of Differentiated Thyroid Cancer

June 25th 2021

Lori Wirth, MD, provides an overview and diagnosis consideration of differentiated thyroid cancer and its related subtypes.

EP. 2: Treatment Options for Patients With Differentiated Thyroid Cancer

June 25th 2021

Lori Wirth, MD, discusses treatment options and potential adverse effects for differentiated thyroid cancer.

EP. 3: Treatment Options for Patients With Radioiodine-Refractory Metastatic Disease

June 25th 2021

Medical oncologist Lori Wirth, MD, discusses treatment options for patients with radioiodine-refractory metastatic disease.

EP. 4: Clinical Practice Implications From the SELECT Trial

June 25th 2021

An overview of how SELECT trial data affected clinical treatment practice for patients with differentiated thyroid cancer.

EP. 5: Post Hoc Analysis of Patients With Lung Metastases from the SELECT Trial

June 25th 2021

Lori Wirth, MD, reviews key efficacy data from the post hoc analysis of the SELECT trial investigating the use of lenvatinib in patients with lung metastases.

EP. 6: Future Considerations in the Management of Differentiated Thyroid Cancer

June 25th 2021

Lori Wirth, MD, discusses unmet needs and future considerations in the management of differentiated thyroid cancer.